event-icon
Description

The utilization of five medications with black box warnings related to pharmacogenomic biomarker was retrospectively assessed at BJC network hospitals in St. Louis over a 5 year period. Although patients had adverse events consistent with those typical of medication side effects, clinicians ordered biomarker testing infrequently. With information from this study, we will improve patient safety by implementing clinical decision support that guides biomarker testing at the time of computerized physician order entry.

Describe the new knowledge and additional skills the participant will gain after attending your presentation.: Testing for biomarkers before administering medications with pharmacogenomic associated FDA black box warning may improve patient safety. It may also allow you to implement effective pharmacogenomic related clinical decision support at your institution.

Authors:

Christopher Suciu (Presenter)
Washington University School of Medicine in St. Louis

Philip Payne, Washington University School of Medicine in St. Louis
Albert Lai, Washington University School of Medicine in St. Louis
Sean Yu, Washington University School of Medicine in St. Louis
Aditi Gupta, Washington University School of Medicine in St. Louis
Eric Hogue, Washington University School of Medicine in St. Louis

Presentation Materials:

Tags